Clinical Research
News & Careers
Search the Site
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login           Employers:  Register | Login   

By Industry | By Industry Segment | By Services and Suppliers | By Location | Profile Search
 Company Profile


Celldex Therapeutics, Inc. 

222 Cameron Drive
Suite 400
Phillipsburg  New Jersey  08865  U.S.A.
Phone: 908-454-7120 Fax: 908-454-1911



 Company News
Celldex Therapeutics, Inc. (CLDX) Announces Appointment To Board Of Directors 12/18/2014 7:58:42 AM
Celldex Therapeutics, Inc. (CLDX) Announces Completion Of Enrollment In Phase 3 Study Of Rindopepimut In Frontline Glioblastoma 12/16/2014 7:37:02 AM
Celldex Therapeutics, Inc. (CLDX) Initiates A Phase 2 Study Of Glembatumumab Vedotin In Patients With Advanced Melanoma 12/5/2014 9:26:07 AM
Celldex Therapeutics, Inc. (CLDX) Release: Interim Update From Randomized Phase 2 ReACT Study Of Rindopepimut In Recurrent Bevacizumab-Naive Glioblastoma Demonstrates Statistically Significant Survival Benefit 11/17/2014 10:30:09 AM
Oncothyreon Inc. (ONTY) And Celldex Therapeutics, Inc. (CLDX) Announce Initiation Of Combination Immunotherapy Clinical Trial Of ONT-10 And Varlilumab 11/11/2014 7:33:42 AM
Celldex Therapeutics, Inc. (CLDX) Presents Varlilumab Proof Of Concept Data At SITC Annual Meeting 2014 11/7/2014 12:17:34 PM
Celldex Therapeutics, Inc. (CLDX) Reports Third Quarter 2014 Results 11/5/2014 7:43:06 AM
Celldex Therapeutics, Inc. (CLDX) Announces Upcoming Presentations of Rindopepimut Data at 19th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology (SNO) 11/3/2014 10:13:46 AM
Celldex Therapeutics, Inc. (CLDX) Announces Publication Of Glembatumumab Vedotin Phase 1/2 Studies In The Journal Of Clinical Oncology 9/30/2014 9:14:10 AM
Celldex Therapeutics, Inc. (CLDX) Initiates Pilot Study Of CDX-301 In Allogeneic Hematopoietic Stem Cell Transplantation 9/25/2014 8:25:28 AM